Equities research analysts forecast that Alimera Sciences Inc (NASDAQ:ALIM) will post sales of $12.97 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Alimera Sciences’ earnings. The lowest sales estimate is $12.94 million and the highest is $13.00 million. Alimera Sciences posted sales of $10.92 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 18.8%. The company is expected to issue its next quarterly earnings results on Monday, July 29th.
On average, analysts expect that Alimera Sciences will report full-year sales of $56.41 million for the current year, with estimates ranging from $55.89 million to $56.92 million. For the next fiscal year, analysts anticipate that the business will report sales of $68.88 million, with estimates ranging from $65.50 million to $72.26 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that that provide coverage for Alimera Sciences.
Alimera Sciences (NASDAQ:ALIM) last issued its quarterly earnings data on Monday, April 29th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.06) by $0.02. The business had revenue of $12.89 million for the quarter, compared to analyst estimates of $12.25 million.
Shares of NASDAQ ALIM traded up $0.01 during midday trading on Friday, hitting $0.87. 35,749 shares of the company’s stock were exchanged, compared to its average volume of 90,824. The business’s 50 day moving average is $0.90. Alimera Sciences has a twelve month low of $0.72 and a twelve month high of $1.21.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Columbia Pacific Advisors LLC acquired a new position in shares of Alimera Sciences in the first quarter worth $54,000. B. Riley Wealth Management Inc. boosted its holdings in Alimera Sciences by 23.5% in the fourth quarter. B. Riley Wealth Management Inc. now owns 101,906 shares of the biopharmaceutical company’s stock worth $73,000 after purchasing an additional 19,407 shares in the last quarter. Royce & Associates LP boosted its holdings in Alimera Sciences by 60.2% in the fourth quarter. Royce & Associates LP now owns 319,186 shares of the biopharmaceutical company’s stock worth $229,000 after purchasing an additional 120,000 shares in the last quarter. Finally, Knott David M boosted its position in shares of Alimera Sciences by 3.9% during the first quarter. Knott David M now owns 402,901 shares of the biopharmaceutical company’s stock worth $427,000 after purchasing an additional 15,000 shares in the last quarter. 50.73% of the stock is currently owned by institutional investors and hedge funds.
Alimera Sciences Company Profile
Alimera Sciences, Inc, a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness.
Featured Story: Elliott Wave Theory
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.